Content about Pharmacology

September 25, 2012

Valeant Pharmaceuticals International has acquired rights to a drug used to treat a symptom of age-related macular degeneration, the drug maker said.

MONTREAL — Valeant Pharmaceuticals International has acquired rights to a drug used to treat a symptom of age-related macular degeneration, the drug maker said.

Valeant announced that it acquired the injected drug Visudyne (verteporfin) from QLT, a company based in Vancouver, Canada.

Valeant said it paid $62.5 million upfront for all U.S. rights and available inventories for the drug, which had U.S. sales of about $21 million in 2011, and another $50 million upfront for rights to non-U.S. sales, which were about $14 million.

September 25, 2012

Generic drug maker Watson Labs recalled two lots of a prescription painkiller due to the potential for oversized and overly potent tablets, the company said.

PARSIPPANY, N.J. — Generic drug maker Watson Labs recalled two lots of a prescription painkiller due to the potential for oversized and overly potent tablets, the company said.

The drug maker announced the recall of hydrocodone bitartrate and acetaminophen tablets in the 10 mg/500 mg strengths based on a customer complaint of tablets that were thicker and darker-colored than the others.

September 25, 2012

For the more than 100 years that Walgreens has been in operation, the company has been focused on helping its customers, communities and patients feel well. And now, it is poised to transform the traditional drug store into a health and daily living destination. 


For the more than 100 years that Walgreens has been in operation, the company has been focused on helping its customers, communities and patients feel well. And now, it is poised to transform the traditional drug store into a health and daily living destination. 


September 25, 2012

There is no doubt about it. Pharmacy audits can be time consuming and laborious for all parties involved. And as both government and commercial money gets tighter and tighter, all of health care is searching for the most effective means to manage the financial challenges associated with doing business. In addition to the clinical aspects, audits are used to identify genuinely fraudulent or erroneously paid healthcare claims. Nevertheless, a survey released in September 2012 by the National Community Pharmacists Association found that nearly 87% of those surveyed stated that reimbursement and auditing practices are “significantly” or “very significantly” affecting their ability to provide patient care and remain in business.

There is no doubt about it. Pharmacy audits can be time consuming and laborious for all parties involved. And as both government and commercial money gets tighter and tighter, all of health care is searching for the most effective means to manage the financial challenges associated with doing business. In addition to the clinical aspects, audits are used to identify genuinely fraudulent or erroneously paid healthcare claims.

September 24, 2012

It wasn’t that long ago that the branded drug industry was seen as an unstoppable titan of American industry, churning out a steady stream of breakthrough therapies and blockbuster products. But a tsunami of expiring patents on such top selling drugs as Lipitor, Plavix and Seroquel, combined with a slowdown in research and development, flattened the growth curve in recent years and opened the door for the ascendancy of generic drugs.

It wasn’t that long ago that the branded drug industry was seen as an unstoppable titan of American industry, churning out a steady stream of breakthrough therapies and blockbuster products. But a tsunami of expiring patents on such top selling drugs as Lipitor, Plavix and Seroquel, combined with a slowdown in research and development, flattened the growth curve in recent years and opened the door for the ascendancy of generic drugs.

September 24, 2012

As part of CVS Caremark's sponsorship of The Partnership at Drugfree.org's The Medicine Abuse Project, which aims to prevent a half-million teens from abusing medicine over the next five years, the company now is asking its customers to take the project's pledge to learn about teen medicine abuse, to safeguard medicines in the home and to talk to teens about this issue, the company announced on Monday.

WOONSOCKET, R.I. — As part of CVS Caremark's sponsorship of The Partnership at Drugfree.org's The Medicine Abuse Project, which aims to prevent a half-million teens from abusing medicine over the next five years, the company now is asking its customers to take the project's pledge to learn about teen medicine abuse, to safeguard medicines in the home and to talk to teens about this issue, the company announced on Monday.

CVS Caremark will use many of its communications channels to share with customers some key facts central to the awareness campaign, such as:

September 24, 2012

The Food and Drug Administration has approved a drug for treating a complication of a disease that results from vein blockages in the eye.

TARRYTOWN, N.Y. — The Food and Drug Administration has approved a drug for treating a complication of a disease that results from vein blockages in the eye.

Regeneron Pharmaceuticals announced the approval of Eylea (aflibercept) for treating macular edema following central retinal vein occlusion, or CRVO. Eylea already was approved for treating neovascular age-related macular degeneration, another eye disease.

September 24, 2012

Generic drug maker Sandoz has launched an authorized generic version of a drug used to treat hypertension.

NEW YORK — Generic drug maker Sandoz has launched an authorized generic version of a drug used to treat hypertension.

The generics division of Swiss drug maker Novartis announced the introduction of valsartan and hydrochlorothiazide tablets, a generic version of Novartis' Diovan HCT. Novartis will continue marketing the branded version of the drug, which had sales of $2.3 billion in 2011 together with Diovan (valsartan).

September 21, 2012

The Food and Drug Administration has approved a new usage for an Amgen drug, the drug maker said.

THOUSAND OAKS, Calif. — The Food and Drug Administration has approved a new usage for an Amgen drug, the drug maker said.

The biotech manufacturer announced the FDA approval of Prolia (denosumab) to increase bone mass in men with osteoporosis who are at high risk for fracture. The drug already was approved for osteoporosis in postmenopausal women.

September 21, 2012

The Food and Drug Administration has approved a blood pressure medication made by Mylan.

PITTSBURGH — The Food and Drug Administration has approved a blood pressure medication made by Mylan.

The drug maker announced Friday the approval of valsartan and hydrochlorothiazide tablets in the 80-mg/12.5-mg, 160-mg/12.5-mg, 160-mg/25-mg, 320-mg/12.5-mg and 320-mg/25-mg strengths.

The drug, a generic version of Novartis' Diovan HCT, is used to treat high blood pressure, or hypertension, in patients who can't control their blood pressure with one drug or who are starting therapy and need multiple drugs.

September 21, 2012

The Food and Drug Administration has approved a generic drug for motion sickness made by Mylan.

PITTSBURGH — The Food and Drug Administration has approved a generic drug for motion sickness made by Mylan.

The drug maker announced Friday that the FDA had approved meclizine hydrochloride tablets in the 12.5-mg, 25-mg and 50-mg strengths. Mylan said it would launch the drug immediately.

The drug is a generic version of Pfizer's Antivert, which is used to treat nausea, vomiting and dizziness associated with motion sickness. Antivert had sales of about $53.5 million during the 12-month period ended in June, according to IMS Health.

September 20, 2012

Alliance Boots, under the terms of a strategic alliance agreement signed earlier this week, announced that it will acquire a 12% stake in Nanjing Pharmaceutical for a total consideration of approximately $90.7 million.

LONDON — Alliance Boots, under the terms of a strategic alliance agreement signed earlier this week, announced that it will acquire a 12% stake in Nanjing Pharmaceutical for a total consideration of approximately $90.7 million. On completion of the transaction, which is subject to various regulatory approvals, Alliance Boots will be the second largest shareholder in Nanjing Pharmaceutical with board and operational management representation.

September 20, 2012

Drug maker Dr. Reddy's Labs has launched a generic antibiotic drug, the company said Thursday.

HYDERABAD, India — Drug maker Dr. Reddy's Labs has launched a generic antibiotic drug, the company said Thursday.

The India-based company announced the launch of amoxicillin tablets, capsules and oral suspension. The tablets are being launched in the 500-mg and 875-mg strengths, while the capsules are in the 250-mg and 500-mg strengths, and the oral suspension is in the 125-mg-, 200-mg-, 250-mg- and 400-mg-per-5-mL strengths.

September 20, 2012

The Food and Drug Administration has approved a drug made by Acton Pharmaceuticals for asthma, the company said Thursday.

MARLBOROUGH, Mass. – The Food and Drug Administration has approved a drug made by Acton Pharmaceuticals for asthma, the company said Thursday.

The drug maker announced the approval of Aerospan (flunisolide HFA) inhalation aerosol as a maintenance treatment for asthma in patients aged 6 and older. The drug maker plans to launch the drug in early 2013.

September 20, 2012

Procter & Gamble this week will begin shipping a wildberry-flavored Prilosec OTC.

NEW YORK — Procter & Gamble this week will begin shipping a wildberry-flavored Prilosec OTC.

The proton-pump inhibitor will not come in a chewable form, however, and will feature the message "Swallow — Do Not Chew" prominently on its packaging.

September 20, 2012

The Senate on Wednesday passed a resolution naming October as National Medicine Abuse Awareness Month.

 WASHINGTON — The Senate on Wednesday passed a resolution naming October as National Medicine Abuse Awareness Month. The resolution was sponsored by Sens. Diane Feinstein, D.-Calif., and Chuck Grassley, R-Iowa, and urges communities to carry out programs and activities to educate parents and youth of the potential dangers associated with medicine abuse.

September 19, 2012

A subsidiary of Johnson & Johnson is hoping to gain Food and Drug Administration approval for a new formulation of one of its drugs.

HORSHAM, Pa. — A subsidiary of Johnson & Johnson is hoping to gain Food and Drug Administration approval for a new formulation of one of its drugs.

Janssen Biotech announced that it had filed an application with the FDA seeking approval for an intravenous formulation of Simponi (golimumab) in adults with moderately to severely active rheumatoid arthritis, which affects an estimated 1.5 million Americans.

September 19, 2012

People go to doctor offices for a variety of reasons — for annual physicals, for checkups after previous appointments, to figure out why something is acting up or if they just feel sick. Whatever the reasons, most of them walk out of the office with a prescription in hand, according to an exclusive survey of nearly 800 patients conducted by AccentHealth and DSN in late July and early August.

People go to doctor offices for a variety of reasons — for annual physicals, for checkups after previous appointments, to figure out why something is acting up or if they just feel sick. Whatever the reasons, most of them walk out of the office with a prescription in hand, according to an exclusive survey of nearly 800 patients conducted by AccentHealth and DSN in late July and early August.

September 18, 2012

Boehringer Ingelheim Pharmaceuticals has launched a drug for treating chronic obstructive pulmonary disease, the company said Tuesday.

RIDGEFIELD, Conn. — Boehringer Ingelheim Pharmaceuticals has launched a drug for treating chronic obstructive pulmonary disease, the company said Tuesday.

BI Pharmaceuticals announced the launch of Combivent Respimat (ipratropium bromide and albuterol), calling it a propellant-free inhaler that uses a slow-moving mist to deliver the same active ingredients as the Combivent metered dose inhaler, requiring one inhalation per dose, compared with Combivent MDI's two inhalations.

September 18, 2012

The Food and Drug Administration has approved a treatment for a disease that causes brittle nails.

CHARLESTON, S.C. — The Food and Drug Administration has approved a treatment for a disease that causes brittle nails.

Innocutis announced the FDA approval of Nuvail (poly-ureaurethane) nail solution in the 16% strength. The drug is used to treat nail dystrophy, which causes fragile and brittle nails that crack and split.

One of the most common forms of nail dystrophy is brittle nail syndrome, which affects about 20% of the population, with women disproportionately affected. Patients with the condition report that their nails are painful and impair daily activities.

September 18, 2012

A trillion of anything is difficult to wrap one’s head around, whether it’s the number of grains of sand on a beach or stars in the sky. It’s so much easier for the human mind to look at such a quantity as the sum of its parts rather than on the basis of its individual components.


A trillion of anything is difficult to wrap one’s head around, whether it’s the number of grains of sand on a beach or stars in the sky. It’s so much easier for the human mind to look at such a quantity as the sum of its parts rather than on the basis of its individual components.


September 18, 2012

The interest in healthcare reform has reached a new high, especially in light of the decision by the U.S. Supreme Court to uphold the Patient Protection and Affordable Care Act, yet there's no denying that consumers are still unclear as to the impact on their personal healthcare and insurance issues. That being said, Americans see a need for change as they battle rising costs and a lack of access to care, and many are saying "aye" to healthcare reform, according to the most recent Patient Views infographic. To be specific, two-thirds of respondents say they support healthcare reform, according to an exclusive survey of nearly 800 patients conducted by AccentHealth and DSN in late July and early August.

The interest in healthcare reform has reached a new high, especially in light of the decision by the U.S. Supreme Court to uphold the Patient Protection and Affordable Care Act, yet there's no denying that consumers are still unclear as to the impact on their personal healthcare and insurance issues. That being said, Americans see a need for change as they battle rising costs and a lack of access to care, and many are saying "aye" to healthcare reform, according to the most recent Patient Views infographic.

September 18, 2012

Earlier this summer Hyland’s introduced its Leg Cramps Ointment to complement its line of homeopathic Leg Cramps tablets. Expect the leg cramp market to grow.

LOS ANGELES — Earlier this summer Hyland’s introduced its Leg Cramps Ointment to complement its line of homeopathic Leg Cramps tablets. Expect the leg cramp market to grow. According to one study, about half of all seniors suffer from leg cramps — they’re more common in women (56%) than men (40%). And two drug classes with strong links to leg cramps include diuretics and the inhaled long-acting B2-agonists 
(e.g., Advair, Serevent, Symbicort).

September 18, 2012

It’s a little hard not to say “Oh, how the mighty have fallen” when a retailer announces that it will give away for free what was once the world’s top-selling drug. But for retailers, it also makes good business sense.


It’s a little hard not to say “Oh, how the mighty have fallen” when a retailer announces that it will give away for free what was once the world’s top-selling drug. But for retailers, it also makes good business sense.


September 18, 2012

Over the last few years of DSN’s coverage of the impending patent cliff and how it would affect the generic drug industry, IMS Health VP industry relations Doug Long predicted that the gradual commoditization of primary care drugs — long the lifeblood of generic drug makers — would lead to consolidation of the industry.


Over the last few years of DSN’s coverage of the impending patent cliff and how it would affect the generic drug industry, IMS Health VP industry relations Doug Long predicted that the gradual commoditization of primary care drugs — long the lifeblood of generic drug makers — would lead to consolidation of the industry.